Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Publication of a New Study Reinforcing the Clinical Association of Its CCL24 Target With Disease Severity and Mortality in Patients With Systemic Sclerosis
Chemomab Therapeutics宣布发表一项新研究，该研究加强了其 CCL24 靶标与系统性硬化症患者疾病严重程度和死亡率的临床关系，此后，该公司股价走高